01 - 05 June 2019
Lisbon, Portugal

Abstracts & Scholarships

Patent Abstracts

Patent abstracts submission is now closed.

Instructions to authors
Carefully read the guidelines below before submitting your patent abstract. Acknowledgement of the receipt of your submission will be sent to the corresponding author’s e-mail address immediately upon submission. If you do not receive the confirmation e-mail, please do not submit the patent abstract again, instead please contact the Patent Abstract Team at eaaci2019patent@eaaci.org for advice.



Patent Abstract Sessions

As during the previous edition, EAACI Congress 2019 will host a session on allergy innovations that are patented or in the process of being patented. Similar to research abstracts, scientific ideas and concepts will be presented and discussed. The session will display the activities of allergy-market
and EAACI’s vision is that this platform will promote funding and support allergy patents, maybe even joint ventures. Risk capital managers as well as pharma industry representatives will be present in these sessions. Young researchers may also be inspired and think about their own patents or
cooperation with innovative ideas. Come and visit this exciting new format and learn about allergy solutions of tomorrow!

Oral patent abstract session: Innovations in Allergy
Sunday, 2 June 2019
12:10-13:20

Poster patent abstract session: Innovations in Allergy
Monday, 3 June 2019
12:15-13:45
Poster Area

 

Terms: Patent Abstract Submission System

1. Authors can modify the author information, category and core data of their abstract directly on the submission system until the deadline given. Please be aware that there will be no extension possible. 

2. Upon your agreement, your abstract, including names, is stored electronically and will be published by the Organising Committee on the EAACI media library and the EAACI website (open access). Failure to present your abstract on-site will result in exclusion from online publishing.

3. No trade names of products are allowed in oral or poster presentations. Non-proprietary (generic, chemical) names of drugs should be used. Company names can be used in the authors’ affiliation and as a source to a material mentioned in the body of the abstract, such as “Imiquimod (3M, Milwaukee, USA) was used to stimulate dendritic cells".

4. Abstracts will be reviewed by an expert panel of reviewers. Acceptance of the submitted work is at the discretion of the Scientific Committee.

5. In case the abstract submitter is not the presenting author, the abstract submitter only receives the abstract submission confirmation email. Further communication will be directed to the presenting author only.  

The presenting author of an abstract must register for the meeting by the given deadline. If EAACI does not receive your registration and payment by the deadline, your abstract will be removed from the programme.

6. Consent for publication of individual patient data - applies to abstracts with identifiable patient information

For the publication of an abstract that contains identifiable information about patients it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).

By agreeing to these terms I confirm that:

a) Written informed consent for publication of this clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient. (Please include a respective statement in your abstract text.)

b) the final decision on whether consent to publish is required lies with EAACI

7. Duplication of publications

EAACI does not accept re-submissions; abstracts must correspond to original, previously unpublished work. By submitting this abstract I confirm that I have not presented/plan to present and publish the abstracts at another meeting, and that I have not submitted/ published the full paper.
 
 

Submission guidelines

You are allowed to be the presenting author of more than one patent abstract.

You are allowed to be a co-author of more than one patent abstract.

Submission of similar patents abstracts from the same group is discouraged.

Please note, a confirmation of consent must be provided in cases where patients, both living or deceased, are visibly identifiable. Should consent not be given, any pictures must be made anonymous by placing sufficient coverage over any identifiable elements; eyes, facial features, characterising marks etc.

Patent abstract language and length
Patent abstracts and presentations must be written in English. The maximum length allowed for a patent abstract is 2500 characters (approximately 350 words) including blank spaces. The patent abstract title, the author(s) or names of institutions are not included in the count of 2500 characters. Tables are allowed - 50 characters per row will be deducted from the word count. Pictures are not allowed.

Presentation formats and patent abstract topics
Accepted patent abstracts selected by expert reviewers will be presented in any of the following sessions: Oral Patent Abstract Sessions or Thematic Poster Sessions (electronic posters). Authors can indicate their choice of preferred type of presentation in the provided space. In addition, authors should indicate the thematic area (see Patent Abstract Topics) their patent abstract should be assigned to. Please note that the final decisions regarding the allocation and the type of presentation of the submitted patent abstract will be made by the Scientific Programme Committee.

It is the author’s responsibility to submit a correct patent abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author as no editing will be done by EAACI. Please note that each year a number of patent abstracts are rejected because of poor English or because they contain no/incomplete data.

Notification of acceptance
Notifications of acceptance or rejection of the abstracts will be sent to the corresponding author of the abstract by March 2019.

The corresponding author receives all correspondence concerning the patent abstract, and is responsible for informing all co-authors of the status of the patent abstract.

With the notification of acceptance, patent abstract presenters will be informed about the time and date of their presentation, and are asked to reconfirm their attendance. EAACI cannot guarantee that presenting authors who do not show up to present their patent abstract during the session will be accepted for patent abstract presentations at future Congresses.

Registration and publication of patent abstracts
The presenting author of a patent abstract must register for the Congress. Until 15 March 2019 the presenting author is offered a special extended “early fee”. The registration fee may be refunded if the patent abstract is rejected. Please note that some countries require a visa to visit Portugal.

Assistance and contact
For any assistance for the submission of the patent abstract please contact the Patent Abstract Team at: eaaci2019patent@eaaci.org





Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel